Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Primary Immunodeficiency Diseases 1Neoplasms 1Infections 1Epstein-Barr Virus Infections 1

Interventions

Cyclophosphamide 641Bevacizumab 552Paclitaxel 534Carboplatin 533Cisplatin 480pembrolizumab 456Gemcitabine 422Docetaxel 415Rituximab 386Radiotherapy 373Dexamethasone 351Doxorubicin 330Nivolumab 308Fluorouracil 286Capecitabine 260Etoposide 245Prednisone 244Oxaliplatin 242Erlotinib Hydrochloride 242Cytarabine 233Lenalidomide 232Trastuzumab 226Pemetrexed 220Vincristine 212fludarabine phosphate 208Leucovorin 208Cetuximab 208Filgrastim 204Bortezomib 193Methotrexate 183

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Has results × threonic acid × Clear all
NCT02496676 2022-03-02

Magnesium Supplementation in People With XMEN Syndrome

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
8 enrolled 7 charts

Primary Immunodeficiency Diseases, Infections, Neoplasms, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡